Home › Companies › IRD

Opus Genetics

Market cap $391M 96.7M shares (10-Q, Nov 6, 2026) × $4.05 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

7 trackedQuarter catalyst calendar →
  1. OPGx-RDH12 trial start4Q 2026OPGx-RDH12 trial start, 4Q 2026, routine
  2. LCA5 program Ph3 start4Q 2026LCA5 program Ph3 start, 4Q 2026, routine
  3. OPGx-BEST1 4.5e9 vg Ph3 topline1Q 2027OPGx-BEST1 4.5e9 vg Ph3 topline, 1Q 2027, thesis-defining
  4. OPGx-MERTK trial start1Q 2027OPGx-MERTK trial start, 1Q 2027, routine
  5. OPGx-BEST1 first dosing Ph3 start2H 2027OPGx-BEST1 first dosing Ph3 start, 2H 2027, notable
  6. OPGx-RHO trial start2H 2027OPGx-RHO trial start, 2H 2027, routine
  7. OPGx-LCA5 corporate updateMar 31, 2028OPGx-LCA5 corporate update, Mar 31, 2028, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (12 active programs)

Capital (as filed)

Cash
$89.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$14.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$89.0M cash, runway into 2029 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on Opus Genetics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Opus Genetics (IRD) — Scientific Deep Dive for OPGx-LCA5, OPGx-BEST1, and the IRD Gene Therapy Pipeline Genuine mechanism-backed clinical signal and elite shareholder register, but ultra-orphan commercial math, N=6/N=1 datasets, pending composition-of-matter on lead asset, and warrant-and-debt-heavy balance sheet leave risk/reward balanced after a 7x run — wait for September 2026 BEST1 Cohort 1 readout.
  2. Speculative buy speculative UPDATE: Opus Genetics (IRD) - The Registrational Trial Is Full Enrollment risk on the registrational LCA5 Phase 3 is retired, the RDEP framework produced an FDA-aligned design with BLA gated to six-month data, and at $3.64 the price is lower than the June watch-list level with the BEST1 readout still ahead — a starter position sized to catalyst risk is warranted.
  3. Speculative buy speculative UPDATE: Opus Genetics (IRD) - The September Date Is Back On September BEST1 date confirmed, LCA5 Phase 3 primary endpoint is public and objective, Phase 3 supply from commercial process retires CMC risk, and $88.8M cash covers both near-term catalysts — speculative buy maintained with no change in conviction.
  4. Speculative buy speculative UPDATE: Opus Genetics (IRD) - Wednesday, 8:00 a.m. ET BEST1 readout date is now fixed for September 9 with a hard timestamp, but a 19.6% pre-catalyst run has narrowed the risk/reward; speculative buy maintained for existing holders while new entrants face a materially worse trade at $4.45.
  5. Hold UPDATE: Opus Genetics (IRD) - The Sentinel Was a Signal BEST1 Cohort 1 delivered clean safety, structural response in 4/5, and an FDA-aligned pivotal endpoint, meaningfully retiring clinical risk, but the stock surged 54% in five weeks and the price took the payment on the same day the data arrived — hold rather than chase.
  6. Hold UPDATE: Opus Genetics (IRD) - The Fine Print Arrives Retina in Rio granular data shows BEST1 microperimetry responses real but thin (3.1–3.5 dB, just above the 3 dB FDA bar), while LCA5 adult durability extends to 24 months — hold because LCA5 de-risked further even though BEST1 fine print reads more like an endpoint-design exercise than a clean efficacy win.
  7. Hold UPDATE: Opus Genetics (IRD) - One Door Opens, Another Closes RDH12 IND cleared on schedule adding a third clinical program, but the Chief Scientific and Development Officer departed weeks before LCA5 Phase 3 dosing with no successor named, adding execution risk at a sensitive moment — hold pending confirmation of first Phase 3 patient dosed.
  8. Hold UPDATE: Opus Genetics (IRD) - Half the Seat Is Filled Science seat refilled within eight days with an AAV vector and potency-assay specialist, slightly reducing leadership-risk discount, but the development half of the old role remains unfilled ahead of LCA5 Phase 3 dosing — hold pending confirmed first patient dosed.
  9. Hold UPDATE: Opus Genetics (IRD) - The Warrant Overhang Clears Most of the warrant overhang converted to equity, book equity turned positive at $38.4M, the Oberland down-round ratchet expired unused, and BEST1 Cohort 2 readout moved up to Q1 2027 — balance-sheet bear points largely retired, but hold pending confirmed LCA5 Phase 3 first dosing.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (8 quotes from 4 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (37)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 3, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

28 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)